Ron DePinho: CRISPR Progress in Cellular Immunotherapy
Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn about a recent article by Heidi Ledford, adding:
”CRISPR progress in cellular immunotherapy …
Researchers used a combination of engineered viruses and virus-like particles to target T cells. The particles carried RNA and protein machinery needed for CRISPR–Cas9 gene editing, and the viruses contained the DNA encoding the CAR protein. T cells had to receive both payloads to become a CAR T cell.
In mice with leukaemia and multiple myeloma, tumors were completely wiped out in the treated mice, and more than half of the treated group with sarcomas entered full remission. A biotechnology company, Azalea Therapeutics is now testing the approach in monkeys and hopes to have clinical trials in people by the end of next year. While encouraging, it remains to be seen how long the effects of the treatment last, or whether CRISPR–Cas9 might be introducing any unwanted changes to the genome.”
Title: CRISPR makes enhanced cancer-fighting immune cells inside mice
Author: Heidi Ledford
Read the Full Article on Nature

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders